Coya Therapeutics got FDA clearance for a Phase 2 trial in the U.S. to investigate COYA 302 as an ALS treatment.| ALS News Today
LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
A Houston-based, clinical-stage immuno-oncology company has raised an oversubscribed round of seed funding.| InnovationMap